Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Stemirna Therapeutics

    • Home
    • Stemirna Therapeutics
Company

Stemirna Therapeutics Halts mRNA Vaccine Factory Construction Amid Low Demand

Fineline Cube Jul 20, 2023

China-based Stemirna Therapeutics Co., Ltd has decided to halt the construction of a factory intended...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos

Fineline Cube Dec 12, 2022

Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...

Recent updates

  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
  • Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
  • Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
  • Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
  • TransThera Tinengotinib Cholangiocarcinoma Priority Review China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.